Xiao-Qing Fan , Shi-Ming Fan , Bi-Ying Dong , Chun-Mei Zhang , Jing Zuo , Dong-Wei Zhang , Xia Xiong , Dan Luo , Xian-Ming Fan
{"title":"Recent advances in the interaction between acute respiratory distress syndrome and gut microbiota: A narrative review","authors":"Xiao-Qing Fan , Shi-Ming Fan , Bi-Ying Dong , Chun-Mei Zhang , Jing Zuo , Dong-Wei Zhang , Xia Xiong , Dan Luo , Xian-Ming Fan","doi":"10.1016/j.meegid.2025.105810","DOIUrl":null,"url":null,"abstract":"<div><div>Acute respiratory distress syndrome (ARDS) is a sudden, widespread inflammatory damage to the lungs resulting from multiple etiologies. ARDS is characterized by high sickness rates, mortality, and costly treatments and is a significant global health issue that lacks an effective treatment strategy. The microbiota of the gut is an intricate ecology indispensable for the host's health, immunology, and metabolism. Human immunity and intestinal barrier function depend on gut microbes. Several disorders are linked to gut microbiota dysbiosis. Scientists have been concentrating on the role that gut microbes play in the onset of ARDS. This study examines the relationship between ARDS and intestinal microbiota, specifically addressing two facets: how ARDS affects the composition of the gut microbiota and the integrity of the intestinal barrier, alongside the effects of mechanisms such as bacterial translocation and inflammatory activation resulting from gut microbiota dysregulation on ARDS. Additionally, various therapeutic strategies involving gut microbiota and its metabolites, such as selective digestive decontamination (SDD), fecal microbiota transplantation (FMT), microbiological preparations, and metabolites produced from the microbiota, are explored. It is anticipated that this exploration will make a substantial contribution to the prevention and therapy of ARDS.</div></div>","PeriodicalId":54986,"journal":{"name":"Infection Genetics and Evolution","volume":"134 ","pages":"Article 105810"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection Genetics and Evolution","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567134825000991","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Acute respiratory distress syndrome (ARDS) is a sudden, widespread inflammatory damage to the lungs resulting from multiple etiologies. ARDS is characterized by high sickness rates, mortality, and costly treatments and is a significant global health issue that lacks an effective treatment strategy. The microbiota of the gut is an intricate ecology indispensable for the host's health, immunology, and metabolism. Human immunity and intestinal barrier function depend on gut microbes. Several disorders are linked to gut microbiota dysbiosis. Scientists have been concentrating on the role that gut microbes play in the onset of ARDS. This study examines the relationship between ARDS and intestinal microbiota, specifically addressing two facets: how ARDS affects the composition of the gut microbiota and the integrity of the intestinal barrier, alongside the effects of mechanisms such as bacterial translocation and inflammatory activation resulting from gut microbiota dysregulation on ARDS. Additionally, various therapeutic strategies involving gut microbiota and its metabolites, such as selective digestive decontamination (SDD), fecal microbiota transplantation (FMT), microbiological preparations, and metabolites produced from the microbiota, are explored. It is anticipated that this exploration will make a substantial contribution to the prevention and therapy of ARDS.
期刊介绍:
(aka Journal of Molecular Epidemiology and Evolutionary Genetics of Infectious Diseases -- MEEGID)
Infectious diseases constitute one of the main challenges to medical science in the coming century. The impressive development of molecular megatechnologies and of bioinformatics have greatly increased our knowledge of the evolution, transmission and pathogenicity of infectious diseases. Research has shown that host susceptibility to many infectious diseases has a genetic basis. Furthermore, much is now known on the molecular epidemiology, evolution and virulence of pathogenic agents, as well as their resistance to drugs, vaccines, and antibiotics. Equally, research on the genetics of disease vectors has greatly improved our understanding of their systematics, has increased our capacity to identify target populations for control or intervention, and has provided detailed information on the mechanisms of insecticide resistance.
However, the genetics and evolutionary biology of hosts, pathogens and vectors have tended to develop as three separate fields of research. This artificial compartmentalisation is of concern due to our growing appreciation of the strong co-evolutionary interactions among hosts, pathogens and vectors.
Infection, Genetics and Evolution and its companion congress [MEEGID](http://www.meegidconference.com/) (for Molecular Epidemiology and Evolutionary Genetics of Infectious Diseases) are the main forum acting for the cross-fertilization between evolutionary science and biomedical research on infectious diseases.
Infection, Genetics and Evolution is the only journal that welcomes articles dealing with the genetics and evolutionary biology of hosts, pathogens and vectors, and coevolution processes among them in relation to infection and disease manifestation. All infectious models enter the scope of the journal, including pathogens of humans, animals and plants, either parasites, fungi, bacteria, viruses or prions. The journal welcomes articles dealing with genetics, population genetics, genomics, postgenomics, gene expression, evolutionary biology, population dynamics, mathematical modeling and bioinformatics. We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .